BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.
F Hoffmann-La Roche Ltd, Teijin Ltd and Chugai Pharmaceutical Co Ltd, under license from Ipsen, are developing the glucagon-like peptide 1 analog BIM-51077, for the potential treatment of type 2 diabetes. Phase II clinical trials are underway, including a phase II trial evaluating a slow release formulation.
Giannoukakis
Nick
N
University of Pittsburgh School of Medicine, Diabetes Institute, Rangos Research Center, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu
D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000201:enzymology; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004353:Drug Evaluation, Preclinical; D052216:Glucagon-Like Peptide 1 / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D013329:Structure-Activity Relationship
C527820:BIM 51077; D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D052216:Glucagon-Like Peptide 1; D018819:Dipeptidyl Peptidase 4